Camrelizumab was recently approved for the treatment of relapsed or refractory Hodgkin lymphoma in China. It is currently being studied for its potential use in SARS-CoV-2 infection. It is an immune checkpoint inhibitor monoclonal antibody (MAb) of programmed cell death protein 1 (PD-1). PD-1 is essential in regulating T cell depletion in sepsis and blocking it can prevent T cell death, reduce organ dysfunction, and regulate cytokine production.